Biosimilar and generic cancer drugs unlikely to bend cost curve in the USA

Charles L. Bennett, Oliver A. Sartor, James Olen Armitage, Hagop Kantarjian

Research output: Contribution to journalComment/debate

6 Citations (Scopus)
Original languageEnglish (US)
Pages (from-to)22-23
Number of pages2
JournalThe Lancet Oncology
Volume18
Issue number1
DOIs
StatePublished - Jan 1 2017

Fingerprint

Biosimilar Pharmaceuticals
Generic Drugs
Costs and Cost Analysis
Neoplasms

ASJC Scopus subject areas

  • Oncology

Cite this

Biosimilar and generic cancer drugs unlikely to bend cost curve in the USA. / Bennett, Charles L.; Sartor, Oliver A.; Armitage, James Olen; Kantarjian, Hagop.

In: The Lancet Oncology, Vol. 18, No. 1, 01.01.2017, p. 22-23.

Research output: Contribution to journalComment/debate

Bennett, Charles L. ; Sartor, Oliver A. ; Armitage, James Olen ; Kantarjian, Hagop. / Biosimilar and generic cancer drugs unlikely to bend cost curve in the USA. In: The Lancet Oncology. 2017 ; Vol. 18, No. 1. pp. 22-23.
@article{34c383c0e3f6478f8e395daa3a34da01,
title = "Biosimilar and generic cancer drugs unlikely to bend cost curve in the USA",
author = "Bennett, {Charles L.} and Sartor, {Oliver A.} and Armitage, {James Olen} and Hagop Kantarjian",
year = "2017",
month = "1",
day = "1",
doi = "10.1016/S1470-2045(16)30653-2",
language = "English (US)",
volume = "18",
pages = "22--23",
journal = "The Lancet Oncology",
issn = "1470-2045",
publisher = "Lancet Publishing Group",
number = "1",

}

TY - JOUR

T1 - Biosimilar and generic cancer drugs unlikely to bend cost curve in the USA

AU - Bennett, Charles L.

AU - Sartor, Oliver A.

AU - Armitage, James Olen

AU - Kantarjian, Hagop

PY - 2017/1/1

Y1 - 2017/1/1

UR - http://www.scopus.com/inward/record.url?scp=85007497510&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85007497510&partnerID=8YFLogxK

U2 - 10.1016/S1470-2045(16)30653-2

DO - 10.1016/S1470-2045(16)30653-2

M3 - Comment/debate

C2 - 28049571

AN - SCOPUS:85007497510

VL - 18

SP - 22

EP - 23

JO - The Lancet Oncology

JF - The Lancet Oncology

SN - 1470-2045

IS - 1

ER -